Volume 5.23 | Jun 17

Hematopoiesis News 5.23 June 17, 2014
Hematopoiesis News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Using deep sequencing of flow-sorted cell populations from chronic lymphocytic leukemia (CLL) patients, investigators established the presence of acquired mutations in multipotent hematopoietic progenitors of CLL patients. Mutations affected known lymphoid oncogenes including BRAF, NOTCH1 and SF3B1. [Cancer Discov] Abstract
ISSCR 2014: Our City. Our Science. Visit us at Booth #817.
PUBLICATIONS (Ranked by impact factor of the journal)

Rapamycin Relieves Lentiviral Vector Transduction Resistance in Human and Mouse Hematopoietic Stem Cells
Scientists showed that rapamycin, an allosteric inhibitor of the mammalian target of rapamycin complexes, facilitates highly efficient lentiviral transduction of mouse and human hematopoietic stem cells and dramatically enhances marking frequency in long-term engrafting cells in mice. [Blood] Abstract

Stem Cell Programs Are Retained in Human Leukemic Lymphoblasts
Whether or not the self-renewal program is retained from stem cells or conferred on progenitors by leukemogenic molecules remains unknown. Investigators addressed the issue in the context of TEL-AML1-associated acute lymphoblastic leukemia by profiling a refined program edited from genes essential for self-renewal of hematopoietic stem cells and B-cell development. [Oncogene] Abstract

Early Exposure of Murine Embryonic Stem Cells to Hematopoietic Cytokines Differentially Directs Definitive Erythropoiesis and Cardiomyogenesis in Alginate Hydrogel Three-Dimensional Cultures
Researchers demonstrate that three-dimensional cultures of alginate-encapsulated murine embryonic stem cells cultured in a rotating wall vessel bioreactor can be differentially driven towards definitive erythropoiesis and cardiomyogenesis in the absence of embryoid-like colony formation. [Stem Cells Dev] Abstract

Non-Marrow Hematopoiesis Occurs in a Hyaluronic Acid-Rich Node and Duct System in Mice
A hyaluronic acid-rich node and duct system was found on the surface of internal organs of mice, and inside their blood and lymph vessels. The nodes were filled with immune cells of the innate system and were especially enriched with mast cells and histiocytes. They also contained hematopoietic progenitor cells such as granulocyte-macrophage, erythroid, multipotential progenitors and mast cell progenitors. [Stem Cells Dev] Abstract

Hypoxia/Hypercapnia-Induced Adaptation Maintains Functional Capacity of Cord Blood Stem and Progenitor Cells at 4°C
Investigators analyzed the effect of exposure to hypoxic/hypercapnic gas mixture on the maintenance of functional cord blood CD34+ hematopoietic stem and progenitor cells in severe hypothermia employing physiological and proteomic approaches. [J Cell Physiol] Abstract

Distinct Stromal Cell Factor Combinations Can Separately Control Hematopoietic Stem Cell Survival, Proliferation, and Self-Renewal
Scientists demonstrate that hematopoietic stem cell (HSC) survival and maintenance of durable self-renewal potential are variably supported by different Steel factor-containing cocktails with similar HSC-mitogenic activities. [Cell Rep] Full Article | Graphical Abstract


Augmented Post-Remission Therapy for a Minimal Residual Disease-Defined High-Risk Subgroup of Children and Young People with Clinical Standard-Risk and Intermediate-Risk Acute Lymphoblastic Leukemia: A Randomized Controlled Trial
No randomized study has shown whether stratification of treatment by minimal residual disease (MRD) response improves outcome in children and young people with acute lymphoblastic leukemia (ALL). Investigators assessed whether children and young people with clinical standard and intermediate-risk ALL who have persistent MRD at the end of induction therapy benefit from augmented post-remission therapy. [Lancet Oncol] Abstract

The HELIOS Trial Protocol: A Phase III Study of Ibrutinib in Combination with Bendamustine and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia
The authors describe the design and rationale for the Phase III HELIOS trial investigating whether ibrutinib added to bendamustine and rituximab (BR) provides benefits over BR alone in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. [Future Oncol] Abstract

Register for new mouse/rat HSC CFU training course
Hematopoietic Stem Cell Transplantation Donor Sources in the 21st Century: Choosing the Ideal Donor When a Perfect Match Doesn’t Exist
In an effort to increase the applicability of transplantation, alternative donors such as mismatched adult unrelated donors, haploidentical related donors, and umbilical cord blood stem cell products are frequently used when a well matched donor is unavailable. We do not yet have the benefit of randomized trials comparing alternative donor stem cell sources to inform the choice of donor; however, data exist to allow some inferences based on existing observational and Phase II studies. [Blood] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
bluebird bio Reports Rapid Transfusion Independence in Beta-Thalassemia Major Patients Treated with Its LentiGlobin Product Candidate
bluebird bio, Inc. released initial positive clinical data from its HGB-205 clinical study of its LentiGlobin BB305 product candidate in beta-thalassemia major subjects. [Press Release from bluebird bio, Inc. discussing research presented research at the 19th Annual Congress of the European Hematology Association (EHA), Milan] Press Release

Results from Phase III Study (AML-001) of VIDAZA® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented
Celgene International Sàrl announced that results from AML-001, its Phase III study of VIDAZA® (azacitidine for injection) compared to conventional care regimens in elderly subjects with newly-diagnosed acute myeloid leukemia were presented. [Press release from Business Wire discussing research presented at the 19th Annual Congress of the European Hematology Association (EHA), Milan] Press Release

Astex Pharmaceuticals Presents Final Results of Phase II Study of SGI-110 in Treatment Naïve Elderly Acute Myeloid Leukemia
Astex Pharmaceuticals presented the final results of a Phase II study of SGI-110, a novel hypomethylating agent in elderly acute myeloid leukemia (AML). The results focused on clinical responses as well as safety of two doses of SGI-110 given as a subcutaneous injection daily x5 every 28 days in treatment naïve elderly AML patients not suitable for intensive chemotherapy enrolled in study SGI-110-01. [Press release from Astex Pharmaceuticals discussing research presented at the 19th Annual Congress of the European Hematology Association (EHA), Milan] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.
CCRM and Stem Cells Australia Agree to Collaborate in the Global Translation of Stem Cell Research
The Centre for Commercialization of Regenerative Medicine (CCRM) and the Stem Cells Australia consortium have entered into a memorandum of understanding to work together to increase the translation of stem cell research in the two countries. [Stem Cells Australia] Press Release

BioLineRx Receives Approval to Commence Phase I Trial for Novel Stem Cell Mobilization Treatment
BioLineRx Ltd. announced that it has received approval from the Israeli Ministry of Health to commence a Phase I trial for BL-8040, a novel treatment for the mobilization of stem cells from the bone marrow to the peripheral blood circulation. [BioLineRx Ltd.] Press Release

Actinium Engages a Leading CRO to Support Phase III Trial of Iomab-B
Actinium Pharmaceuticals, Inc. announced that it has executed an agreement with ACT Oncology, a full-service clinical research organization (CRO), to utilize their services for a number of clinical development-related projects. This agreement includes the preparations for the Phase III clinical trial of Iomab-B, a myeloconditioning drug for bone marrow transplant preparation. [Actinium Pharmaceuticals, Inc.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW South Central Association of Blood Banks & Association of Donor Recruitment Professionals Joint Educational Symposium
July 18, 2014
Fort Worth, United States

Visit our events page to see a complete list of events in the hematopoiesis research community.
NEW Postdoctoral Research Fellow – Cardiovascular Immunology / Hematology (Massachusetts General Hospital)

Research Associate – Hematopoietic and Leukemic Stem Cells (Shanghai Jiao-Tong University School of Medicine)

Postdoctoral Position/Clinical Pharmacist – Hematopoiesis and Laboratory for Cell Therapy (Sanquin)

Clinical HSCT Faculty Position – Pediatric Hematology-Oncology (University of Wisconsin School of Medicine)

Postdoctoral Research Scientist – Stem Cell Biology and Cellular Immunology (The Anthony Nolan Trust)

Postdoctoral Fellow – Mammalian Hematopoietic and Erythroid Development (Icahn School of Medicine at Mount Sinai)

Postdoctoral Fellow – Regulation of Cytokine Receptor Signaling in Hematopoietic Stem Cells (University of Pennsylvania School of Medicine)

Postdoctoral Positions – New Models of Hematopoiesis and Hematopoietic Disorders (Icahn School of Medicine at Mount Sinai)

Postdoctoral Researcher – Cancer Genomics (University of Chicago)

Postdoctoral Associate – Hematopoietic Differentiation (Northwestern University Feinberg School of Medicine)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us